Interim report January-June 2015
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014.Continued growth of Zubsolv® in high-value commercial segment – driven by expanded field force and improved market access position Second quarter 2015 · Total net revenues amounted to MSEK 126.5 (117.3). · Earnings after tax were MSEK -84.6 (-50.2). · Earnings per share were SEK -2.46 (-1.58). · Cash flow from operating activities amounted to MSEK -35.6 (-228.2). · Orexo divested the subsidiary Kibion; short term negative net impact of
